Search

Your search keyword '"Mackay, Alan"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Mackay, Alan" Remove constraint Author: "Mackay, Alan" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
200 results on '"Mackay, Alan"'

Search Results

1. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

2. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

3. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

4. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

5. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

6. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

7. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

8. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

9. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

10. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

11. Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

12. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

13. Supplementary Data from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition

14. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

15. Supplementary Table 3 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

16. Supplementary Table 2 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

17. Data from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

18. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

19. Press Conference from Functional Viability Profiles of Breast Cancer

20. Supplementary Table 2 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

21. Data from Functional Viability Profiles of Breast Cancer

22. Supplementary Methods from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

23. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

24. Data from Functional Viability Profiles of Breast Cancer

25. Supplementary Table S5 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

26. Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

27. Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

28. Supplementary Figures S1-S3 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

29. Supplementary Table S3 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

30. Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

31. Supplementary Table 3 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

32. Supplementary Table S1 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

33. Data from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

34. Supplementary Figure Legends from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

35. Supplementary Table S2 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

36. Supplementary Table S6 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

37. Supplementary Table S7 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

38. Press Conference from Functional Viability Profiles of Breast Cancer

39. Supplementary Figure Legends from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

40. Supplementary Table S5 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

41. Supplementary Data from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

42. Supplementary Table 1 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

43. Supplementary Table 4 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

44. Supplementary Methods from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

45. Supplementary Figures 1 - 13 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

46. Data from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

47. Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

48. Supplementary Table 4 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

49. Supplementary Table S6 from Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes

50. Supplementary Figures 1 - 13 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN

Catalog

Books, media, physical & digital resources